Genomic Valley Biotech

Genomic Valley Biotech Forward P/E

Delisted·Sep 16, 2026

The Forward P/E Ratio of Genomic Valley Biotech (539206.BO) as of Oct 17, 2026 is 19.30. In the previous year, Forward P/E Ratio was 452.77 — a change of -95.74% (lower).

Forward P/E

19.30

YoY

-95.74%

Last updated:

Forward P/E Ratio of Genomic Valley Biotech is 2025 19.30 . Forward P/E Ratio of Genomic Valley Biotech was 2024 452.77 . It decreases by -95.74% lower compared to the previous year.

The Genomic Valley Biotech Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2022
-735.87 INR
Jan 1, 2023
10.60 INR
Jan 1, 2024
452.77 INR
Jan 1, 2025
19.30 INR
The Genomic Valley Biotech Forward P/E history
YEARForward P/EYoY
19.30-95.74%
452.77+4,170.42%
10.60-101.44%
-735.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Valley Biotech Stock analysis

What does Genomic Valley Biotech do? Genomic Valley Biotech Ltd, identified by the ticker symbol 539206.BO and the ISIN code INE574D01010, is an Indian corporate entity established within the biotechnology and life sciences sector. The company maintains its primary operational headquarters in Bahadurgarh, a city located in the state of Haryana, India. This geographical positioning places the firm within a significant industrial and technological hub in northern India, facilitating its business operations and strategic partnerships within the regional ecosystem. The organization entered the public equity markets through an Initial Public Offering that was officially executed on July 10, 2015. This milestone marked a critical transition in the company's corporate history, allowing it to raise capital from public investors and increase its visibility within the financial markets. The listing on the Bombay Stock Exchange under the specified ticker provides a mechanism for public trading and valuation of the company's shares. While specific details regarding its industry classification and sector categorization are not explicitly defined in the available reference data, the company's name and operational focus imply a specialization in genomic technologies and biotechnological solutions. The corporate profile is further accessible through its official digital presence at http://www.genomicvalley.com/, where stakeholders and interested parties can obtain additional information regarding its business activities, corporate governance, and financial performance. As a publicly traded entity, Genomic Valley Biotech Ltd is subject to the regulatory frameworks and disclosure requirements mandated by Indian securities regulators. The company's journey from its foundational establishment to its public listing in 2015 represents a structured growth trajectory aimed at expanding its reach and capabilities in the competitive biotech landscape. Investors and analysts monitoring the Indian market may track the company's performance through its stock ticker, utilizing the ISIN for precise identification in global financial databases. The lack of explicit sector or industry tags in the provided data does not diminish the company's operational identity, which remains anchored in the scientific and technological advancements associated with genomics and biotechnology. The headquarters in Bahadurgarh serves as the central node for administrative, research, and strategic decision-making processes, supporting the company's ongoing initiatives and market engagements. Genomic Valley Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Valley Biotech stock

Forward P/E Ratio of Genomic Valley Biotech is 19.30 in 2025.

Forward P/E Ratio of Genomic Valley Biotech changed from 452.77 to 19.30, representing a -95.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Genomic Valley Biotech since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Genomic Valley Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genomic Valley Biotech

All Key Metrics — Genomic Valley Biotech